UK markets closed
NIKKEI 225
38,236.07 -38.03 (-0.10%) HANG SENG
18,475.92 0.00 (0.00%) CRUDE OIL
78.41 +0.30 (+0.38%) GOLD FUTURES
2,314.50 +5.90 (+0.26%) DOW
38,675.68 +449.98 (+1.18%) Bitcoin GBP
51,235.85 +845.91 (+1.68%)
ACIU Nov 2024 2.500 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 12:30PM EDT. Market open.
| Previous close | 0.7000 |
| Open | 0.7000 |
| Bid | 0.0000 |
| Ask | 0.8500 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.7000 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 35 |
Simply Wall St.We Think AC Immune (NASDAQ:ACIU) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- Simply Wall St.
Further weakness as AC Immune (NASDAQ:ACIU) drops 12% this week, taking three-year losses to 58%
AC Immune SA ( NASDAQ:ACIU ) shareholders should be happy to see the share price up 17% in the last month. But over the...
Globe NewswireAC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease on track for interim data in H2ACI-24.060 for Alzheimer’s disease (AD) received FDA Fast Track designationACI-35.030 ReTain Phase 2b program in preclinical (pre-symptomatic) AD patients, initiated by collaboration partnerCash of CHF 103 million at year end, plus the CHF 15 million
© 2024 Yahoo. All rights reserved.